LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more
LegoChem Biosciences Inc (141080) - Net Assets
Latest net assets as of September 2025: ₩563.07 Billion KRW
Based on the latest financial reports, LegoChem Biosciences Inc (141080) has net assets worth ₩563.07 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩699.43 Billion) and total liabilities (₩136.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩563.07 Billion |
| % of Total Assets | 80.5% |
| Annual Growth Rate | 40.84% |
| 5-Year Change | 449.38% |
| 10-Year Change | 1326.64% |
| Growth Volatility | 101.38 |
LegoChem Biosciences Inc - Net Assets Trend (2014–2024)
This chart illustrates how LegoChem Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LegoChem Biosciences Inc (2014–2024)
The table below shows the annual net assets of LegoChem Biosciences Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩616.00 Billion | +315.59% |
| 2023-12-31 | ₩148.22 Billion | -32.50% |
| 2022-12-31 | ₩219.60 Billion | -15.14% |
| 2021-12-31 | ₩258.77 Billion | +130.79% |
| 2020-12-31 | ₩112.13 Billion | -1.43% |
| 2019-12-31 | ₩113.75 Billion | +11.89% |
| 2018-12-31 | ₩101.66 Billion | +110.89% |
| 2017-12-31 | ₩48.21 Billion | -19.74% |
| 2016-12-31 | ₩60.06 Billion | +39.10% |
| 2015-12-31 | ₩43.18 Billion | +115.42% |
| 2014-12-31 | ₩20.04 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to LegoChem Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6476500497000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩36.33 Billion | 5.90% |
| Other Components | ₩579.67 Billion | 94.10% |
| Total Equity | ₩616.00 Billion | 100.00% |
LegoChem Biosciences Inc Competitors by Market Cap
The table below lists competitors of LegoChem Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MIRION TECHNOL. DL-0001
F:55I0
|
$3.68 Billion |
|
easyJet plc
OTCQX:EJTTF
|
$3.69 Billion |
|
MISC Bhd
KLSE:3816
|
$3.69 Billion |
|
Lifco AB (publ)
PINK:LFCBY
|
$3.69 Billion |
|
Dajin Heavy Industry Corp
SHE:002487
|
$3.68 Billion |
|
Sectra AB (publ)
ST:SECT-B
|
$3.68 Billion |
|
Dolby Laboratories
NYSE:DLB
|
$3.68 Billion |
|
MERIDIAN ENERGY
F:15M1
|
$3.68 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LegoChem Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 148,221,267,200 to 615,998,105,850, a change of 467,776,838,650 (315.6%).
- Net income of 7,800,099,580 contributed positively to equity growth.
- Share repurchases of 455,720,674,700 reduced equity.
- New share issuances of 475,677,051,500 increased equity.
- Other factors increased equity by 440,020,362,270.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩7.80 Billion | +1.27% |
| Share Repurchases | ₩455.72 Billion | -73.98% |
| Share Issuances | ₩475.68 Billion | +77.22% |
| Other Changes | ₩440.02 Billion | +71.43% |
| Total Change | ₩- | 315.59% |
Book Value vs Market Value Analysis
This analysis compares LegoChem Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 69.85x to 12.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3020.78 | ₩211000.00 | x |
| 2017-12-31 | ₩2421.32 | ₩211000.00 | x |
| 2018-12-31 | ₩4800.09 | ₩211000.00 | x |
| 2019-12-31 | ₩5304.51 | ₩211000.00 | x |
| 2020-12-31 | ₩4734.30 | ₩211000.00 | x |
| 2021-12-31 | ₩10677.76 | ₩211000.00 | x |
| 2022-12-31 | ₩8610.70 | ₩211000.00 | x |
| 2023-12-31 | ₩5566.42 | ₩211000.00 | x |
| 2024-12-31 | ₩16978.06 | ₩211000.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LegoChem Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.20%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.20x
- Recent ROE (1.27%) is above the historical average (-19.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -43.33% | -998.29% | 0.03x | 1.68x | ₩-10.69 Billion |
| 2015 | -19.08% | -460.58% | 0.03x | 1.59x | ₩-12.56 Billion |
| 2016 | -24.52% | -88.41% | 0.19x | 1.49x | ₩-20.73 Billion |
| 2017 | -26.83% | -58.64% | 0.27x | 1.71x | ₩-17.75 Billion |
| 2018 | -25.35% | -102.10% | 0.21x | 1.20x | ₩-35.94 Billion |
| 2019 | 11.94% | 23.63% | 0.41x | 1.24x | ₩2.21 Billion |
| 2020 | -6.23% | -14.14% | 0.36x | 1.21x | ₩-18.20 Billion |
| 2021 | -9.04% | -72.74% | 0.11x | 1.13x | ₩-49.27 Billion |
| 2022 | -20.53% | -134.96% | 0.13x | 1.15x | ₩-67.05 Billion |
| 2023 | -49.73% | -215.85% | 0.18x | 1.28x | ₩-88.53 Billion |
| 2024 | 1.27% | 6.20% | 0.17x | 1.20x | ₩-53.80 Billion |
Industry Comparison
This section compares LegoChem Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $259,224,420,269
- Average return on equity (ROE) among peers: -0.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LegoChem Biosciences Inc (141080) | ₩563.07 Billion | -43.33% | 0.24x | $3.68 Billion |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.37 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $229.70 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $409.02 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $453.92 Million |
| GeneOne Life Science Inc (011000) | $23.71 Billion | -35.27% | 0.34x | $52.94 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $14.76 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.92 Billion | 8.17% | 0.31x | $27.84 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $964.67 Million |
| iNtRON Biotechnology Inc (048530) | $49.15 Billion | -1.24% | 0.21x | $83.99 Million |
| Synergy Innovation Co. Ltd (048870) | $71.09 Billion | 0.00% | 0.77x | $77.78 Million |